Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance

Gynecologic Oncology
Joseph P Connor, Mildred Felder

Abstract

Decoy receptor 3 (DcR3), a soluble tumor necrosis factor receptor is a known binding partner of multiple apoptotic ligands inhibiting apoptosis. The expression of DcR3 by cancers has been reported in gastrointestinal cancers yet it has not been described in ovarian cancer. Abnormalities in apoptosis pathways are seen in ovarian cancer and we theorized that the presence of DcR3 is a component of the dysregulation. Ascites samples from 44 women with advanced ovarian cancer were tested for DcR3 by ELISA. The ability of ascites to inhibit Fas-ligand mediated apoptosis was determined by chromium release assays using cell surface or soluble Fas-ligand. Clinical parameters including, response to platinum and progression free and overall survival were compared between patients with high or low levels of DcR3. DcR3 was found in all 44 cases by ELISA. Ascites fluid significantly inhibited Fas-ligand mediate apoptosis using both surface Fas-ligand (KFL-9 cells) and soluble Fas-ligand. Blocking DcR3 with antibodies restores the cytolytic effects in both assays. HIGH DcR3 level was associated with stage IV disease and more than double the incidence of platinum resistant disease. In this modest sample size Low DcR3 cases had longer PFI and o...Continue Reading

References

May 13, 2003·International Journal of Cancer. Journal International Du Cancer·Yulian WuJiangping Wu
Feb 12, 2004·Journal of Immunological Methods·Jinguo ChenSunghee Kim
Sep 24, 2004·International Journal of Cancer. Journal International Du Cancer·Elieser GorelikAnna E Lokshin
Jan 22, 2005·Cancer Immunology, Immunotherapy : CII·Yuru MengDavid A Fishman

❮ Previous
Next ❯

Citations

Apr 26, 2014·World Journal of Gastroenterology : WJG·Liang ZongDa-Xin Wang
Apr 25, 2012·Cancer Metastasis Reviews·Katharine L SodekMaurice J Ringuette
Dec 19, 2012·Journal of the Chinese Medical Association : JCMA·En-Pen ChangTung-Po Huang
Jan 11, 2011·Cancer Letters·Marco de BruynWijnand Helfrich
Apr 25, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Jian ZhouShi-Ying Zheng
Sep 7, 2016·Canadian Journal of Gastroenterology & Hepatology·Giorgos BamiasSpiros D Ladas
Apr 27, 2019·Proteomics. Clinical Applications·Xing WuJian Zhou
May 27, 2010·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Faustino R Pérez-LópezJuan M Troyano-Luque
Oct 28, 2010·Upsala Journal of Medical Sciences·Meisongzhu YangDianzhong Luo
Jun 2, 2016·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Mengtong JiangGang Chen
May 5, 2018·Experimental and Therapeutic Medicine·Tuanjie ZhaoJixiang Wu
Mar 31, 2010·Journal of Ovarian Research·Jennifer Aa GubbelsManish S Patankar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis